Received: from nobody by stodi.digitalkingdom.org with local (Exim 4.80.1) (envelope-from ) id 1W3W5f-0007ER-2G for lojban-newreal@lojban.org; Wed, 15 Jan 2014 11:25:27 -0800 Received: from dmd164.mail14.dmdelivery.com ([58.220.14.164]:35812) by stodi.digitalkingdom.org with esmtp (Exim 4.80.1) (envelope-from ) id 1W3W5X-0007Db-S0 for lojban@lojban.org; Wed, 15 Jan 2014 11:25:26 -0800 Received: by dmd164.mail14.dmdelivery.com id hqrg9u1b9rkr for ; Thu, 16 Jan 2014 01:25:09 +0800 (envelope-from ) MIME-Version: 1.0 Message-Id: To: lojban@lojban.org From: "Joseph Li" Reply-To: "Joseph Li" Subject: Would you like a discussion of Col1a2? X-Mailer: DMD-MTA X-Hash: S7Y1Nv2fa2tobmD5v8jWwtTCzMLof46toYWR2f8M29SU3JzUkpLUIhO9xCTdnMykosSiSr3k.Nz.mSm2CBEAA88 List-Id: <660.edmletter4.ab-library.com> List-Help: List-Owner: Content-Type: multipart/alternative; boundary="D138980670967200916" Date: Thu, 16 Jan 2014 03:25:19 +0800 X-Spam-Score: 3.4 (+++) X-Spam_score: 3.4 X-Spam_score_int: 34 X-Spam_bar: +++ X-Spam-Report: Spam detection software, running on the system "stodi.digitalkingdom.org", has identified this incoming email as possible spam. The original message has been attached to this so you can view it (if it isn't spam) or label similar future email. If you have any questions, see the administrator of that system for details. Content preview: text Would you like a discussion of Col1a2? Dear Professor, [...] Content analysis details: (3.4 points, 5.0 required) pts rule name description ---- ---------------------- -------------------------------------------------- 1.6 RCVD_IN_BRBL_LASTEXT RBL: RCVD_IN_BRBL_LASTEXT [58.220.14.164 listed in bb.barracudacentral.org] -0.0 SPF_PASS SPF: sender matches SPF record 0.0 MIME_HTML_MOSTLY BODY: Multipart message mostly text/html MIME 0.0 HTML_MESSAGE BODY: HTML included in message 0.7 MPART_ALT_DIFF BODY: HTML and text parts are different 1.0 HTML_IMAGE_ONLY_16 BODY: HTML: images with 1200-1600 bytes of words --D138980670967200916 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable text --D138980670967200916 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable <= style type=3D"text/css">.ReadMsgBody { width: 100%; }.ExternalClass { width= : 100%; }#outlook a { padding: 0 0 0 0; }body { -webkit-text-size-adjust: n= one; -ms-text-size-adjust: none;} Would you like a discussi= on of Col1a2? =0A Dear Professor,

=0AMy name i= s Joe Lim. I happened to find some of your excellent papers made a mention = of Col1a2. As I understand that Col1a2 lacks reliable antibodies for 'high-= end' applications such as IP/ChIP, I am curious if you would be interested = in our service of developing custom antibodies against it.

=0AIf you= like, we would be very happy to send you the custom antibody design analys= is, production plan, product and quality guarantee and quote for Col1a2. Pe= rhaps we could further discuss the antibody development and possible applic= ations.

=0AIf you are interested in other proteins for antibody deve= lopments, please also feel free to reply with the sequence or accession num= ber. We could conduct a tentative protein analysis for you within two busin= ess days.

=0AThank you very much and looking forward to your reply,<= br>
=0ABest regards,

=0AJoe

=0AJoe Lim, PhD
=0ABusiness= Development Manager
=0AA b - m a r t=0A3D""/=0A --D138980670967200916--